Shire selects two groups for orphan drug distribution
Specialty pharmacy Caremark was been chosen by Shire Human Genetics Therapies to participate in a limited distribution network for idursulfase (Elaprase), the orphan drug recently approved to treat Hunter Syndrome, or mucopolysaccharidosis II.
Shire selects two groups for orphan drug distribution
Specialty pharmacy Caremark was been chosen by Shire Human Genetics Therapies to participate in a limited distribution network for idursulfase (Elaprase), the orphan drug recently approved to treat Hunter Syndrome, or mucopolysaccharidosis II. One of two companies selected, Caremark will provide distribution, pharmacy, and patient care services for the introduction of the therapy in the U.S. The other participating specialty pharmacy will be Accredo Nova Factor.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
How Differences in Bispecific Therapies Impact Myeloma Treatment Operations
April 18th 2024According to Kirollos Hanna, PharmD, although similarities exist between bispecific therapies in the myeloma space, health care providers should take special note of practical differences and nuances associated with each when operationalizing them at their site of care.
